San Diego-based Viking Therapeutics marked itself as a serious competitor in the weight loss drug sector in February soon after revealing promising data from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection and in March the company unveiled programs